Retracted: Evaluation of the effect of pentoxifylline on white blood cell count in serum and peritoneal fluid in female rats with endometriosis

article OA: closed CC0 RETRACTED ⤵ 5 in-corpus citations
Retraction notice. Marked retracted by OpenAlex; see publisher for the formal retraction notice.
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-07

Pentoxifylline administration significantly reduced endometrial implant size and altered white blood cell counts in serum, including decreasing total white blood cells and neutrophils while increasing lymphocytes, in rats with surgically induced endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AIM: Endometriosis is defined as the growth of endometrium outside of the uterus in ectopic places. Immune system disturbances have an important role in endometriosis which may lead to infertility. It seems that inflammatory cytokines, specially tumor necrosis factor-alpha (TNF-alpha), which are produced by activated macrophages, play an important role in the pathology of endometriosis. Based on this theory, anti-TNF-alpha drugs are suggested as new drugs for endometriosis. This experimental study has been performed on female rats to determine the effect of pentoxifylline on the white blood cell count in serum and peritoneal fluid. METHODS: During the proestrous phase, one horn of the bicorn uterus of rats was removed surgically, and the endometrium implanted to different places as follows: subcutaneous, peritoneum and near the ovaries. After 2 months' observation, female rats were divided randomly into two groups. The treated group (n = 10) were given pentoxifylline (5 mg/kg twice a day), and the control group (n = 10) were given normal saline (the same dose), which was injected subcutaneously. Then via second laparotomy and in the same phase of the cycles, the size of implants and the white blood cell levels in the serum and peritoneum were measured. RESULTS: In the treated group, the total implant mass (mm2) decreased significantly in the right subcutaneous (8.05 mm2 vs 13.5 mm2; P = 0.01), left subcutaneous (7.64 mm2 vs 14.00 mm2; P = 0.01), right ovary (6.64 mm2 vs 15.22 mm2; P = 0.001) and left ovary (7.18 mm2 vs 14.56 mm2; P = 0.005). The total white blood cell count (5254.5455 +/- 178.73 vs 15,833.33 +/- 259.27; P = 0.02) and neutrophils (297.34 +/- 57.34 vs 2736.00 +/- 346.75; P = < 0.001) in the serum were decreased and the total count of lymphocytes (4967.92 +/- 696.194 vs 13,048.33 +/- 178.73; P = 0.003) in serum was increased. There were not any significant changes in the total white blood cell count in the peritoneum in both groups. The number of estrous cycles in both groups was similar. CONCLUSION: Based on our study, pentoxifylline could decrease the size of endometrial implants, especially in the ovaries and subcutaneous areas, and total white blood cell count in serum. Pentoxifylline could increase the lymphocyte count and decrease the neutrophil count in serum, and because these changes it might alter the immune system. Pentoxifylline did not have any adverse effect on rats' cycles and a good aspect of treatment with pentoxifylline was achieved.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Ascitic Fluid Endometriosis Endometriosis Leukocyte Count Pentoxifylline Animals Ascitic Fluid Endometriosis Endometriosis Female Neutrophils Pentoxifylline Pentoxifylline Rats Rats, Sprague-Dawley Tumor Necrosis Factor-alpha Tumor Necrosis Factor-alpha

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (24)

Cited by (5)

Source provenance

europepmc
last seen: 2026-06-20T06:14:18.781669+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:30.652814+00:00
License: CC0 · commercial use OK